Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Searcey

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Current Pharmaceutical Design|June 8, 2002
Duocarmycins--natures prodrugs?Mark Searcey
Current Medicinal Chemistry. Anti-Cancer Agents|September 24, 2004
Resistance in cancer: a target for drug discoveryMark Searcey, Laurence H Patterson
Drug News & Perspectives|July 11, 2006
Cancer treatments for the new millenniumRobert Williams, Mark Searcey, Barry Potter
Drug News & Perspectives|June 19, 2008
Recent disclosures of clinical drug candidatesRichard E Armer, Phillip Cowley, Mark Searcey
Trends in Pharmacological Sciences|October 31, 2024
Advances in triterpene drug discoveryZoë R Goddard, Mark Searcey, Anne Osbourn
Bioorganic & Medicinal Chemistry|June 28, 2022
Junctions in DNA: underexplored targets for therapeutic interventionEleanor Ivens, Marco M D Cominetti, Mark Searcey
Bioorganic & Medicinal Chemistry Letters|March 15, 2018
Perfluoroarene-based peptide macrocycles that inhibit the Nrf2/Keap1 interactionRichard J Steel, Maria A O'Connell, Mark Searcey
The Journal of Organic Chemistry|July 9, 2021
Synthesis and Evaluation of Duocarmycin and CC-1065 Analogues Containing Modifications in the Subunit Linking AmideDale L Boger, Alejandro Santillán, Mark Searcey, et al.
Current Topics in Medicinal Chemistry|November 12, 2009
Chemical and biological explorations of the family of CC-1065 and the duocarmycin natural productsNandita Ghosh, Helen M Sheldrake, Mark Searcey, et al.
Natural Product Reports|February 3, 2007
Bisintercalator natural products with potential therapeutic applications: isolation, structure determination, synthetic and biological studiesSimon Dawson, John P Malkinson, David Paumier, et al.
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Current Pharmaceutical Design|June 8, 2002
Duocarmycins--natures prodrugs?Mark Searcey
Current Medicinal Chemistry. Anti-Cancer Agents|September 24, 2004
Resistance in cancer: a target for drug discoveryMark Searcey, Laurence H Patterson
Drug News & Perspectives|July 11, 2006
Cancer treatments for the new millenniumRobert Williams, Mark Searcey, Barry Potter
Drug News & Perspectives|June 19, 2008
Recent disclosures of clinical drug candidatesRichard E Armer, Phillip Cowley, Mark Searcey
Trends in Pharmacological Sciences|October 31, 2024
Advances in triterpene drug discoveryZoë R Goddard, Mark Searcey, Anne Osbourn
Bioorganic & Medicinal Chemistry|June 28, 2022
Junctions in DNA: underexplored targets for therapeutic interventionEleanor Ivens, Marco M D Cominetti, Mark Searcey
Bioorganic & Medicinal Chemistry Letters|March 15, 2018
Perfluoroarene-based peptide macrocycles that inhibit the Nrf2/Keap1 interactionRichard J Steel, Maria A O'Connell, Mark Searcey
The Journal of Organic Chemistry|July 9, 2021
Synthesis and Evaluation of Duocarmycin and CC-1065 Analogues Containing Modifications in the Subunit Linking AmideDale L Boger, Alejandro Santillán, Mark Searcey, et al.
Current Topics in Medicinal Chemistry|November 12, 2009
Chemical and biological explorations of the family of CC-1065 and the duocarmycin natural productsNandita Ghosh, Helen M Sheldrake, Mark Searcey, et al.
Natural Product Reports|February 3, 2007
Bisintercalator natural products with potential therapeutic applications: isolation, structure determination, synthetic and biological studiesSimon Dawson, John P Malkinson, David Paumier, et al.
Pageof 6